Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to -$20.1 million.

  • Ani Pharmaceuticals' Net Income towards Common Stockholders rose 206.92% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.0 million, marking a year-over-year increase of 547.54%. This contributed to the annual value of -$20.1 million for FY2024, which is 217.45% down from last year.
  • According to the latest figures from FY2024, Ani Pharmaceuticals' Net Income towards Common Stockholders is -$20.1 million, which was down 217.45% from $17.2 million recorded in FY2023.
  • Ani Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $17.2 million for FY2023, and its period low was -$49.5 million during FY2022.
  • Over the past 3 years, Ani Pharmaceuticals' median Net Income towards Common Stockholders value was -$20.1 million (recorded in 2024), while the average stood at -$17.5 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 470.00% in 2020, then soared by 134.64% in 2023.
  • Yearly analysis of 5 years shows Ani Pharmaceuticals' Net Income towards Common Stockholders stood at -$22.5 million in 2020, then slumped by 89.79% to -$42.8 million in 2021, then fell by 15.72% to -$49.5 million in 2022, then surged by 134.64% to $17.2 million in 2023, then crashed by 217.45% to -$20.1 million in 2024.